GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » PT Indofarma Tbk (ISX:INAF) » Definitions » Quality Rank

PT Indofarma Tbk (ISX:INAF) Quality Rank


View and export this data going back to 2001. Start your Free Trial

What is PT Indofarma Tbk Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

PT Indofarma Tbk Quality Rank Related Terms

Thank you for viewing the detailed overview of PT Indofarma Tbk's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Indofarma Tbk (ISX:INAF) Business Description

Traded in Other Exchanges
N/A
Address
Jalan Indofarma No. 1, Cikarang Barat, Jawa Bara, Bekasi, IDN, 17530
PT Indofarma Tbk is a specialty and generic drug manufacturing company. The company has four business segments - Medicine, Medical Devices and others, Pharmaceutical Engineering, and Aliansi Strategis Segment. The Medicine business segment includes drug production, marketing and distribution and sales. The Medical Device Segment includes medical devices and other products. The Pharmaceutical Engineering Segment includes the sale and maintenance of packaging machines for the pharmaceutical industry to external parties.